Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia: A Multicenter Trial of the European Myeloma Network

NCT01046006 is registered in ClinicalTrials.gov with Meletios A. Dimopoulos as lead sponsor.

NCT NCT01046006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01046006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia: A Multicenter Trial of the European Myeloma Network
Lead sponsor
Meletios A. Dimopoulos
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2007
Completion date
November 30, 2015
Enrollment
59 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

waldenstrom's macroglobulinemia